Biogen Inc. (BIIB) Earnings Call Transcript & Summary

July 22, 2020

NASDAQ US Health Care Biotechnology earnings 73 min

Earnings Call Speaker Segments

Joe Mara

executive
#1

Hello, and welcome to the Biogen earnings call for the second quarter of 2020. Before we get started, I'd ask that all of you visit the investors section on biogen.com, where you can locate the earnings release along with the most recent financial tables — among them a reconciliation of GAAP to non-GAAP financial measures that we'll be covering today. Tables 1 and 2 contain our GAAP financials. In table 3, you'll find a reconciliation of our GAAP to non-GAAP financial results, as well as our GAAP to non-GAAP financial guidance. It's our view that non-GAAP financial results give a better picture of the ongoing economics of our business and show how we run it internally; in addition, we've put slides on our website that relate to and accompany this discussion. I want to note that we'll be making forward-looking statements, which rest on what we currently expect and believe. Certain risks and uncertainties apply to these statements. What actually happens could differ materially. For more detail, I'd suggest reviewing the risk factors covered in our SEC filings. Joining me on today's call are our Chief Executive Officer, Michel Vounatsos, Dr. Alfred Sandrock, EVP, Research and Development, and Jeffrey Capello, our CFO. I'll now hand the call over to Michel.

Michel Vounatsos

executive
#2

Good morning, everyone, and thanks for being with us today. By concentrating on executing well, we've kept serving patients, moved our strategic priorities forward, and turned in yet another solid financial quarter. I'd like to start by covering a few key developments. To begin, our submission seeking approval in the U.S. for aducanumab is now complete — an extraordinary opportunity for patients and for Biogen to potentially deliver the first therapy that reduces the devastating clinical decline and meaningfully alters the course of Alzheimer's disease. I feel immense pride in the Biogen team for their commitment and relentless effort that got our regulatory submission finished on July 7th. We submitted this filing following ongoing cooperation with the FDA. It includes information gathered through an extensive clinical development effort. That effort involved EMERGE, which stands as the first phase III trial in this field to produce positive findings, plus supportive information from the phase III ENGAGE trial and favorable outcomes from the phase I-B PRIME trial. According to what our findings show, aducanumab could potentially reduce declines in cognitive ability and support patients in managing particular everyday tasks — something that, for certain individuals, may translate into living without assistance for an extended period. Turning to the next steps: once we submit, we anticipate hearing from the FDA within 60 days about whether it has been accepted, and, assuming it is, whether it will receive priority review. We plan to announce both of those outcomes by way of a press release. On the U.S. launch readiness front, we've continued to advance, which includes broadening our medical work with experts and thought leaders, allowing us to gain a clearer picture of how aducanumab could shape clinical practice. Our efforts to engage payers have started to gain traction, and we've been spelling out the value proposition for aducanumab. A cross-functional team dedicated to site readiness has been established and is up and running now. Outside the U.S., we saw considerable progress during the quarter. We've had official discussions with regulators in the EU as we prepare to hand in a filing. Our work on getting ready to launch in Europe is beginning to accelerate. Over in Japan, we've engaged in unofficial talks with regulators and are preparing for a formal consultation with the PMDA. Overall, together with Eisai, our collaboration partner, we remain hopeful about the chance to bring aducanumab to the market as the first treatment that can meaningfully alter the course of Alzheimer's disease, and we have continued to move forward with our market preparation and launch readiness, starting with a focus on the U.S. From where we stand, aducanumab marks the beginning of a new chapter in possible Alzheimer's therapies, and we aim to create a wide-ranging franchise that covers several targets and modalities. This includes BAN2401, currently in phase III, which we're working on alongside Eisai, plus a fresh trial focused on preclinical Alzheimer's. It also takes in numerous programs aimed at tau, as well as our partnership with Sangamo to create gene regulation treatments for various neurological conditions, Alzheimer's disease among them. Our belief is that Biogen holds a distinctive position to spearhead the battle against Alzheimer's disease in both the near term and further out. Moving on, we're displeased with the recent court decision in West Virginia regarding the patent we possess for TECFIDERA. That decision is being challenged on appeal, and our intention is to defend our intellectual property aggressively. Regardless of how things ultimately turn out, our view remains that Biogen is in a strong position to create shareholder value as we pursue growth opportunities within our core business. We think we're uniquely situated, and that now is the moment for Biogen to take the lead as this space evolves. Our pipeline is deep, with 29 clinical assets, among them 7 that are in phase III or already filed, plus 7 data readouts from mid to late-stage programs expected before 2021 ends. There are near-term chances to create value beyond Alzheimer's disease in other significant areas, including ALS, ophthalmology, lupus, and stroke. And third, as was announced yesterday, Jeff will step away from the CFO role in August. I want to express thanks to Jeff for everything he has contributed to this company, from building a very strong team, to helping produce consistent quarter-over-quarter results, to improving our finance processes and operations, and to fostering a culture of disciplined cost management. We're glad Jeff will remain for a short while to make sure the transition goes smoothly. We wish him success in whatever he does next. Now I'll go through how we performed in Q2 and how we're progressing on our strategic priorities. Measured against the same period last year, revenues for the second quarter rose 2%, reaching $3.7 billion. For Q2, GAAP earnings per share climbed 22% to $9.59, while non-GAAP EPS was up 12% to $10.28. Importantly, momentum improved during June after COVID-19 had an effect earlier in the quarter. To start, Q2 MS revenues, which include Ocrevus royalties, came to $2.3 billion. Globally, the count of patients using our MS product rose 3% compared with the prior year, and our business kept showing resilience. Our MS portfolio delivered strong market share performance this quarter, with a greater share of new prescriptions in the U.S. and market share in Europe that stabilized. On the whole, our fumarate products had a solid quarter, since we concentrated on getting the most out of TECFIDERA and VUMERITY together. Even though VUMERITY's performance let us down, it's worth noting that the U.S. MS market has been hit hard by fewer new patient starts and switchers because of COVID-19, along with less engagement with physicians, and both of those things have weighed on the VUMERITY launch. Importantly, we think the market is becoming more and more aware that VUMERITY is clearly differentiated when it comes to better GI tolerability and could be a better treatment option for a large number of MS patients. Looking ahead, our strategic focus is on Vumerity now, and we're putting more resources toward it so we can maximize this next generation fumarate. We hope that this approach, together with a possible recovery in the dynamic portion of the market, will help Vumerity's trajectory improve during the second half of the year. Outside of the U.S. During this quarter, we felt a great deal of satisfaction in having turned in the regulatory submission for Vumerity across Canada and Switzerland, and our intention is to submit in the EU before this year concludes. Apologies. A vital element of our approach in MS is, and will keep on being, putting resources into lifecycle management along with creative new methods aimed at tackling whatever unmet medical needs still remain; we anticipate the opicinumab readout later this year, which might deliver a groundbreaking new way to slow down or perhaps even turn around the worsening of disability by means of remyelination. Alongside opicinumab, we keep moving BIIB061 forward, an oral remyelination treatment, plus BIIB091, an oral BTK inhibitor whose profile could be best-in-class. Our view is that this significant asset might strengthen our extensive lineup of MS therapies down the road. Throughout our existing MS offerings, keeping lifecycle management front and center remains a top priority; not long ago we sought approval for a subcutaneous version in both the U.S. and EU, aiming to provide a competitive dosing profile within the high-efficacy arena. We keep pushing ahead with the possible application of extended interval dosing for TYSABRI; we are progressing an intramuscular form of plerixafor that could enhance its tolerability. We are making use of label updates concerning interferon use while pregnant.

Michel Vounatsos

executive
#3

Our dedication to MS hasn't changed, and no matter how the TECFIDERA litigation turns out, our attention is on getting the most out of the wide range of possibilities available to us through products we currently offer and those still to come. Moving on to SPINRAZA. Global revenues for SPINRAZA during the second quarter reached $495 million, which is 1% higher than the same period last year. Given the dosing setbacks caused by COVID-19 — which were worst in mid-April before starting to ease in May and June — we consider this a solid result. When you count the expanded access program along with clinical trials, more than 11,000 patients are receiving SPINRAZA, which is 30% more than a year earlier. During this quarter, at the virtual Cure SMA Meeting, we shared significant new findings that revealed an unmatched survival benefit for pre-symptomatic SMA patients who received SPINRAZA. Results from the NURTURE study keep showing the powerful advantages SPINRAZA is able to offer patients. This comes after independent real-world data was published earlier in the year, which showed the benefits of real clinical significance that SPINRAZA can provide for teenagers and adults — the group making up the biggest share of the market. SPINRAZA remains the sole treatment cleared for SMA patients across every age group, delivering efficacy that is clinically meaningful and sustained in all age categories; we just recently made public our intention to launch a fresh clinical trial assessing how safe and effective SPINRAZA is when given to infants after gene therapy; we feel there is a solid scientific basis and a substantial need to look into what extra benefit SPINRAZA might offer this population. Real-world demand for SPINRAZA in this context has been evident, with 40% of patients in the long-term extension of the phase I gene therapy study subsequently going on to get SPINRAZA. As part of our lifecycle management efforts in SMA, we are also looking into whether a higher dose of Spinraza might deliver even better efficacy, which is what the DEVOTE study is examining. Second-quarter biosimilars revenues came to $172 million, since we saw an effect from COVID-19, especially during the early part of the quarter; we calculate that in 2019 our biosimilars produced roughly €1.8 billion in savings for European healthcare systems, and we anticipate that figure will keep growing in 2020. This matters as we strive to open up financial room for innovation and help ensure healthcare systems remain sustainable over the long term. Samsung Bioepis recently kicked off a phase III trial for our prospective biosimilar that references Eylea, while we push to broaden into ophthalmology and extra markets, such as Japan and the U.S. In addition to Alzheimer's disease, we keep advancing our pipeline. We launched a new phase I trial in movement disorders. We shared favorable first-in-class data for BIIB059 in cutaneous lupus erythematosus. The encouraging phase I-II findings for tofersen in SOD1 ALS appeared in the "New England Journal of Medicine." Fifth, our ability to generate cash flow is still robust and keeps giving us considerable optionality and flexibility for allocating capital. During Q2, we brought in roughly $2 billion in cash flow from operations. Our balance sheet holds $5.3 billion in cash and marketable securities, which gives us the financial room to keep assessing external business development and M&A possibilities. We've shown before that our commitment is to maximize shareholder returns while striving to deliver innovative therapies to patients. That calls for a considered strategy toward every investment we make, near term and long term alike. To wrap up, Biogen keeps executing well against our strategy, including the BLA submission for aducanumab in the U.S. that happened recently. Although we're aware of the possible risk surrounding Tecfidera, we think our position is strong as we keep constructing a multi-franchise portfolio, drawing on how interconnected our deep neuroscience pipeline is; by the end of next year, we anticipate seven significant mid-to-late stage readouts. Beyond Alzheimer's, we have multiple chances to create meaningful value in areas of high unmet medical need, such as ALS, ophthalmology, lupus, and stroke, plus ongoing innovation in MS and SMA. I'll hand the call to Al now so he can provide a more detailed update on our recent R&D progress.

Alfred Sandrock

executive
#4

Thanks, Michel. Morning, everybody. First off, I want to express appreciation to the Biogen team for all their efforts as they keep pushing our R&D programs forward through these difficult times. While there's still some uncertainty about how COVID-19 is affecting our studies, I'm glad to report that most of our clinical trials remain on schedule or are only a bit behind, and we anticipate seven mid-to-late stage readouts before next year wraps up. Now let me shift to the progress achieved across our pipeline in Q2. Beginning with Alzheimer's disease, as Michel noted, our BLA submission for aducanumab has been completed with the FDA. That filing rests on EMERGE, which stands as the initial positive phase III trial of a therapy intended to lessen clinical decline in Alzheimer's disease. It also draws on supporting data from ENGAGE, even though that trial missed its primary endpoint, along with favorable findings from the phase I-B PRIME study; we took part in a pre-BLA meeting with the FDA, and in it the agency restated that a BLA grounded in data from EMERGE, ENGAGE, and PRIME was reasonable. We're eager to collaborate with the FDA throughout their review and to keep up our dialogue with other regulators globally. I'd like to congratulate the team for hitting this significant milestone amid the COVID-19 crisis. We're also pressing ahead with a wider Alzheimer's disease portfolio and feel we're well-positioned to sustain leadership in this therapeutic area. A piece of this approach involves moving into even earlier patient populations, aiming to delay or possibly even prevent the clinical onset of the disease. Toward that goal, our collaboration partner, Eisai, together with the Alzheimer's Clinical Trials Consortium, announced the launch of the AHEAD 3 to 45 clinical study to assess BAN2401 in people with preclinical Alzheimer's disease. Such individuals have intermediate or elevated amyloid levels in their brains. Combined, the A3 and A45 studies will determine whether giving BAN2401 early can hold back the progression of amyloid and tau pathology and lessen cognitive decline in the very earliest stages of Alzheimer's disease. Findings from the BAN2401 phase II study, along with the parallels between BAN2401 and aducanumab, give us grounds for optimism about the ongoing phase III trial of BAN2401 in early Alzheimer's disease. Past amyloid beta, we keep advancing multiple programs targeting various drug targets, among them tau, which in its misfolded state forms the main component of neurofibrillary tangles, a hallmark of Alzheimer's pathology. The buildup and spread of misfolded tau within the brain tracks with disease progression and might render it suitable for clearance through antibody-based methods, which we think target extracellular forms of the protein. Our foremost tau asset is gosuranemab, a monoclonal antibody now in a phase II study for Alzheimer's disease; enrollment for this study is complete, with data anticipated in the first half of next year. Alongside gosuranemab, we also have BIIB076, a separate anti-tau antibody in phase I. We're making progress as well with our antisense oligonucleotide aimed at tau, BIIB080, which has the potential to lower production of every version of that protein, whether inside cells or outside them. Shifting to our multiple sclerosis portfolio, we keep pushing forward on several efforts designed to further unlock value from the franchise we already have. Along those lines, at the AAN meeting in May we shared fresh data spanning our MS portfolio. That data included new findings on TYSABRI, which backed up earlier results showing that dosing at extended intervals comes with a reduced rate of PML and might preserve similar efficacy as measured through serum neurofilament light biomarkers. Whether extended-interval dosing delivers efficacy comparable to the standard regimen is now under prospective evaluation in the ongoing NOVA study, with a readout anticipated during the first half of next year; beyond that, we're chasing approaches in MS that we hope will prove transformative. The furthest along asset in our MS pipeline is opicinumab, also called anti-LINGO-1, a potential first-in-class remyelination therapy intended to encourage neuronal repair and possibly reverse disability in MS. Right now, the Phase II-B AFFINITY trial is evaluating how safe and effective opicinumab is when added on top of existing disease-modifying therapies for MS. AFFINITY draws on information from the earlier SYNERGY phase II study in MS along with a later post-hoc analysis to pin down what we consider additional criteria required for identifying the right patients, the right dose, and the right measurements for assessing opicinumab's therapeutic potential; we also have an oral remyelination candidate, BIIB061, sitting in phase I with a target that differs from anti-LINGO's. Then there's BIIB091, a small molecule BTK inhibitor in phase I. In our view, the highly potent and selective non-covalent way BIIB091 inhibits BTK could make it a best-in-class molecule. Moving over to neuromuscular disorders, at this past month's Cure SMA meeting we gave an update on the ongoing NURTURE study. NURTURE represents the longest study ever conducted on treating pre-symptomatic SMA patients, and it assesses nusinersen in infants whose treatment began soon after birth and before symptoms appeared. The latest analysis revealed that every one of the 25 children, or 100%, up to 4.8 years of age were still alive and had no need for permanent ventilation, while 88% walked on their own and 96% could walk with assistance. We're happy to share that nusinersen's U.S. label was updated not long ago to incorporate the extra data collected through NURTURE. In ALS, findings from the phase I/II trial of tofersen among patients whose genetic ALS stems from SOD1 mutations appeared this month in "The New England Journal of Medicine"; that study demonstrated encouraging efficacy signals across a number of clinical and biomarker endpoints. These results give us encouragement, and we're eager for outcomes from the ongoing phase III VALOR study, which should read out late next year. We think the tofersen findings carry favorable readouts for the rest of our ALS assets, such as BIIB078 for ALS tied to mutations in C9orf72 — the most frequent genetic root of the condition — plus our ataxin-2 targeted program. Now I'd like to discuss the encouraging strides we're making in lupus. At last month's European Congress of Rheumatology, we shared data from our phase II LILAC trial, which assessed the safety and efficacy of BIIB059 — a fully humanized monoclonal antibody aimed at BDCA-2 — in people with active cutaneous lupus erythematosus, or CLE, whether or not systemic manifestations were present. Treatment with BIIB059 produced a dose response on the CLASI-A score, a well-defined and reliable outcome measure for detecting CLE skin disease activity. To be specific, study participants with CLE who received BIIB059 demonstrated statistically significant reductions in CLASI-A score at week 16 compared with placebo, with a P value on the primary endpoint of less than 0.001. Biogen scientists discovered and developed BIIB059, which could become the first anti-BDCA-2 antibody for treating lupus; we intend to launch a phase III program for BIIB059 during the first half of next year. Working alongside our partner, UCB, we plan to kick off in Q3 of this year the phase III program for dapirolizumab pegol in patients who have active systemic lupus erythematosus despite receiving standard of care therapies. That phase III program comes on the heels of promising phase II-B clinical trial results, interim data from which were presented at EULAR in June of 2019. With BIIB059 and dapirolizumab pegol together, both in late-stage development, we're well-positioned to potentially build a meaningful franchise in lupus, a disease where patients need better treatment options. Shifting to ophthalmology, we keep advancing our gene therapy programs for inherited retinal disorders, among them BIIB111 for choroideremia and BIIB112 for X-linked retinitis pigmentosa, both conditions lacking approved treatments. We anticipate data from the phase III study of BIIB111 during the first half of next year. Notably, that marks our next pivotal readout and our next potential commercial product following aducanumab. We likewise anticipate data from the phase II/III study of BIIB112 in the first half of 2021. We're pleased to have signed a licensing agreement with Massachusetts Eye and Ear Infirmary to develop a potential treatment for inherited retinal degeneration caused by mutations in the PRPF31 gene, which rank among the most common causes of autosomal dominant retinitis pigmentosa. To sum up, we keep moving forward a broad and deep pipeline centered on neuroscience, aimed at capitalizing on the breaking science, including advancements in imaging, CSF, and blood-based biomarkers, and the significant unmet need in this space as we strive to create a multi-franchise portfolio. We have a large number of anticipated mid to late-stage readouts coming through the close of next year, spanning a varied group of key therapeutic areas — MS, ALS, ophthalmology, Parkinson's disease, stroke, and Alzheimer's disease. Our pipeline, we think, will provide ongoing innovation that helps push the company's long-term growth. Now I'll hand the call over to Jeff.

Jeffrey Capello

executive
#5

Thanks, Al. Good morning, all. We're happy that Biogen delivered another robust quarter even with the hurdles posed by COVID-19, since we kept executing at a high level. Our financial standing remains very solid, with considerable cash and financial capacity to keep expanding the business over the long haul. I'll now walk through our financial results for the quarter and give an update on our full-year guidance. Second quarter total revenues rose 2% compared with the same period last year, reaching $3.7 billion. As a reminder, we believe Q1 2020 revenues carried a benefit of roughly $100 million tied to pulled-forward sales because of the COVID-19 pandemic, and we believe about $75 million of that was drawn down during this year's second quarter. On the whole, we performed well in our MS business, posting $2.3 billion in second quarter revenues, which includes OCREVUS royalties of $208 million, a 2% decline versus the prior year. Without OCREVUS royalties, global MS revenues for the second quarter fell 4% versus the prior year. Importantly, given today's COVID-19 conditions, we believe our MS products are well-positioned against the competition, based on treatment guidelines from the MS International Federation. U.S. MS revenues, excluding OCREVUS, came in approximately flat versus the prior year. We were quite encouraged to see growth in share of new prescriptions for fumarates, TYSABRI and interferons during the quarter, despite the recent uptick in competition. Outside the U.S., our MS revenues reached $615 million, down 11% versus the prior year, partly because of a negative foreign exchange impact of approximately $35 million. Also, we believe first quarter 2020 MS revenues outside the U.S. carried a benefit of approximately $59 million tied to pulled-forward sales because of the COVID-19 pandemic, and we believe roughly $37 million of that was drawn down in the second quarter. Importantly, outside the U.S., we achieved solid patient growth of 7%, as our leading MS therapies continued to be very well received. Global second quarter fumarate revenues, covering both Tecfidera and Vumerity, rose 3% versus the prior year, lifted by revenue growth in the U.S. In the U.S., fumarate revenue increased 6% versus the prior year. U.S. fumarate revenues were affected by a channel inventory increase of approximately $15 million in the second quarter of 2020, versus a decrease of approximately $15 million in last year's second quarter. Second quarter VUMERITY revenue came to $9 million. We now have access and reimbursement covering the vast majority of commercial lives. Within the U.S., we were pleased to see strong execution, with growth in our share of both new and total prescriptions for the fumarates versus the prior quarter. As Michel mentioned, we are boosting our resource allocation for VUMERITY. It's important to note that COVID-19 is affecting overall new prescription volumes in the U.S., which makes new product launches more challenging, including for VUMERITY. When we look outside America, TECFIDERA's revenue for the second quarter of 2020 fell 4%, as demand increases were canceled out by pricing and adverse currency movements. Our view is that Q1 2020 TECFIDERA revenue from outside America contained a gain of roughly $28 million tied to sales that were pulled forward because of the COVID-19 pandemic, and we think about $17 million of that was drawn down during Q2 2020. The key point is that patients on TECFIDERA outside America rose roughly 12% compared with the prior year, powered by patient growth in Europe of about double digits and about 38% patient growth in Latin America and Asia-Pacific when those regions are combined. For Q2, worldwide interferon revenue, covering AVONEX as well as PLEGRIDY, dropped 13% against Q2 2019, reflecting the ongoing move away from injectable platforms toward oral or high efficacy therapies. Here in America, interferon revenue fell 9% against the prior year; we were happy to observe gains in share of new prescriptions and a steady share of total prescriptions during the second quarter, which is something we had not witnessed for quite a while, since interest in the interferons has kept rising ever since the COVID-19 pandemic started. Beyond America, interferon revenue dropped 22% against the prior year. Our view is that first quarter 2020 interferon revenue from outside America contained a gain of roughly $21 million tied to sales pulled forward because of the COVID-19 pandemic, and we think about $15 million of that was drawn down during the second quarter of this year. TYSABRI revenue globally fell 9% against the second quarter of 2019. In America, TYSABRI revenue fell 8% against the prior year, and we estimate that inventory dynamics and the effects of COVID-19 contributed equally, given postponed dosing at infusion sites. Inside America, we were happy to observe roughly flat adjusted volumes and share of new prescriptions against the prior quarter. Beyond America, TYSABRI revenue fell 11% against the prior year, hurt by roughly $12 million from adverse currency movements plus channel dynamics; our view is that Q1 2020 TYSABRI revenue from outside America contained a gain of roughly $7 million tied to sales pulled forward because of the COVID-19 pandemic, and we think about $5 million of that was drawn down during the second quarter of 2020. Outside America, we were happy to observe ongoing patient growth of 5% for TYSABRI against the prior year; our view is that TYSABRI is well positioned to take on a growing role in treating MS, through several key initiatives, such as pursuing subcutaneous administration of TYSABRI, the potential for extended interval dosing, and a home infusion option; we were happy with how our MS franchise executed and with the sustained strong results of our MS business during the second quarter; we stay focused on maximizing the resilience of our market-leading franchise. Now let me turn to SPINRAZA. Worldwide SPINRAZA revenue for the second quarter rose 1% against the prior year, reaching $495 million. In America, revenue fell 9% against the second quarter of 2019 and fell 11% against the first quarter of 2020. The count of individuals receiving therapy within the United States rose 6% year over year, while dropping a bit from the previous quarter, which we attribute to COVID-19 affecting the beginning of treatment for new patients. COVID-19 left its mark on the U.S. SPINRAZA business during the second quarter; even so, we felt good about how we executed overall, since additional centers resumed operations and the vast majority of patients kept getting their therapy, albeit with certain delays in dosing. Maintenance doses showed a solid gain in June, and we closed out the quarter carrying positive momentum. Beyond the United States, SPINRAZA revenue grew 10% against the second quarter of 2019, which reflects robust results even with COVID-19's effects. We achieved widespread expansion throughout every major region globally, with a growing roster of nations contributing as this highly successful product launch continues. Equally significant, it gives us encouragement that independent real-world data recently published regarding SPINRAZA's use among adults has assisted us in obtaining wider reimbursement for older patients across certain European markets. On the whole, we felt good about how SPINRAZA performed during the second quarter, notwithstanding COVID-19's difficulties. Equally significant, our current estimate puts the number of SMA patients across global markets at more than 60,000, and we anticipate commercializing a figure substantially above our earlier projection of 45,000.

Jeffrey Capello

executive
#6

We continue to see growth opportunities for this well-established product, thanks to SPINRAZA's efficacy and the strength of our real-world evidence, along with a substantial number of patients who remain untreated across numerous established and emerging markets. Turning now to biosimilars, that business brought in $172 million during the quarter, a decline of 7%, partly reflecting market dynamics tied to COVID-19. In our view, first quarter 2020 biosimilar revenues contained a benefit of roughly $15 million tied to accelerated sales from the COVID-19 pandemic, and we believe about $9 million of that was used in Q2 2020. During the second quarter, biosimilars revenue was hurt as well. The reason was a relatively bigger decline in patients beginning new immunology therapies, which stemmed from COVID-19, and that impacted both comparisons against last year and against the previous quarter. Our estimate is that about 215,000 patients in Europe are currently on our biosimilars. In the major EU5 markets, BENEPALI remained the most prescribed ENBREL biosimilar. Compared with a year earlier, Flixabi volumes increased 58%, and Imraldi volumes increased 46%. Although COVID-19 did weigh on our biosimilars business in the quarter, we can continue expanding in Europe and possibly in the U.S. and other regions through our other assets. During Q2, anti-CD20 revenue overall declined 17% year over year. Higher Ocrevus royalties were more than offset by reduced Rituxan sales stemming from COVID-19 effects and ongoing biosimilar pressure. Meanwhile, other revenues for the quarter climbed 155% compared with a year earlier. That jump came mainly from roughly $330 million tied to licensing certain manufacturing-related intellectual property to one of our corporate partners, which flowed through contract manufacturing revenues. Keep in mind, we had expected this deal back in 2020. Now shifting to gross margins: Q2 2020 gross margin reached 89%, up from 87% a year ago thanks to higher-margin contract manufacturing revenue, and also better than the previous quarter. For Q2, GAAP R&D came in at 18% of revenue, while non-GAAP was 15% of revenue. During the second quarter, we booked $208 million in GAAP expenses and $125 million in non-GAAP R&D expenses, both tied to our Sangamo Therapeutics collaboration. SG&A for Q2 was 15% of revenue on both a GAAP and non-GAAP basis; we continue to anticipate that SG&A will rise during the back half of the year as we scale up commercial readiness efforts for aducanumab. GAAP other income for Q2 totaled $63 million, including $103 million of unrealized investment gains, mainly reflecting higher fair value for our equity stakes in Ionis Pharmaceuticals and Sangamo. On a non-GAAP basis, other expense for Q2 came to $30 million. Our effective GAAP tax rate this Q2 was around 22%, which is higher than the roughly 14% we saw in the second quarter of 2019. Two things drove that: a prior-year income tax benefit tied to a change in our tax profile that won't recur, plus a current-year income tax expense stemming from a net valuation allowance. As for our effective non-GAAP tax rate, it landed at about 19% during Q2 2020, compared with roughly 14% in Q2 2019 — mainly attributable to the one-time benefit from the tax profile change we made last year. Turning to buybacks, we repurchased approximately 9 million shares in the second quarter at an average price of $313, for a total of about $2.8 billion. When Q2 ended, roughly $1.3 billion was still left for buying back stock through the program approved in December 2019. Next is earnings per share on a diluted basis. During Q2, GAAP EPS came in at $9.59, which is 22% higher than the same period last year, while non-GAAP EPS reached $10.26, marking a 12% gain versus a year ago. Our operations generated about $1.95 billion of net cash flow in Q2. As the quarter wrapped up, we held $5.3 billion in cash plus marketable securities, and our debt stood at $7 billion. I'll now turn to the updated outlook we have for all of 2020. Because many things might impact the intellectual property circumstances surrounding TECFIDERA, the guidance we revised leaves out any operational impact from a potential generic launch during this year. If we go with that premise, our projection for revenue lands somewhere between about $13.8 billion and $14.2 billion. On a GAAP basis, R&D spending should represent about 16% to 17% of overall revenue. For SG&A, we're looking at roughly 17.5% to 18.5% of total revenue on both a GAAP and non-GAAP basis. The tax rate we're modeling is approximately 18.5% to 19.5% under GAAP, and about 18% to 19% on a non-GAAP basis. For the full year 2020, we're anticipating GAAP diluted EPS of $32 to $34, with non-GAAP diluted EPS coming in between $34 and $36. One thing to keep in mind: this outlook doesn't factor in anything from possible acquisitions or major business development deals, as those are incredibly hard to forecast. Our assumptions also include a steady share count relative to Q2 2020 and no movement in foreign exchange rates. As I bring my remarks to a close, I want to share that being Biogen's CFO has been a truly rewarding experience for me. The contributions I've been able to make are something I take pride in. In my view, Biogen now stands in a stronger position to generate long-term shareholder value, with numerous opportunities lying ahead. To everyone on the Biogen team, I extend my best wishes for the future. At this point, I'll return the call to Michel so he can offer his closing comments.

Michel Vounatsos

executive
#7

Thanks a lot, Jeff. This quarter, Biogen once more showed it can execute at a high level. Once again we posted robust financial performance, moved our plan of constructing a portfolio spanning multiple franchises ahead significantly, and — which matters greatly — drew nearer to a possible green light for aducanumab, which would be the initial treatment capable of lessening clinical decline in Alzheimer's disease. I'd like to restate how dedicated we are to boosting shareholder returns as much as possible and to delivering breakthrough medicines to patients both right now and far into the future. To do that, we must keep putting capital to work in ways that are efficient, effective, and suitable. Just as we've shown before, we will at all times seek an ideal capital structure while also targeting outstanding results from what we invest in. Lastly, our company treats the racial injustice incidents of late, along with the substantial health inequity that persists — brought into focus by the COVID-19 crisis — with the utmost seriousness. Today more than at any prior point, we're concentrating on pushing forward our wider mission as an organization, striving to break new ground in science for humanity's benefit. That encompasses acting rightly toward patients, our staff, the planet, and the community — each of which, in our view, feeds into durable shareholder value across the long haul. It likewise encompasses speeding up what we're doing on diversity and inclusion throughout the company, a space in which Biogen had already occupied a front-running spot, spanning recruitment through how we run clinical trials and our work to guarantee that those most at risk can obtain our medicines. What Biogen represents makes me proud, and I think this way of doing things leaves us well placed to be a lasting organization over the long run, since we stay fixed on leading in neuroscience to tackle the enormous societal requirements in this field. Once more, I want to express gratitude to our team members worldwide who commit themselves to creating a beneficial difference in patients' lives, which includes securing access to our medicines throughout these demanding times. Having said that, we'll now take questions on the call.

Joe Mara

executive
#8

Just a quick note before we go on — since quite a few analysts have joined this call, we'd be grateful if you could stick to asking a single question. Thanks so much.

Cory Kasimov

analyst
#9

Hi there, good morning everyone, and thanks for taking my questions. First off, Jeff, it's been a pleasure collaborating with you during your time at Biogen. I'd like to ask about the phase III trial in pre-symptomatic Alzheimer's that was announced recently. Could you walk us through why BAN 2401 was selected instead of aducanumab? What was it about that particular asset that made it the more appealing choice for moving into this setting first? Is it because no dose titrations are needed, or is there another reason? Thanks very much.

Alfred Sandrock

executive
#10

Cory, Al Sandrock here. Honestly, I only caught every third word you said, so I'm not certain, but my guess is you were asking about BAN2401 in preclinical Alzheimer's disease and maybe how it compares with aducanumab. Assuming that's right, I'd tell you that yes, BAN2401 and aducanumab are quite similar antibodies. Each of them favors binding to aggregated forms of A-beta, and each demonstrates a strong effect on amyloid PET imaging. In addition, both have demonstrated a decrease in clinical decline in phase II or phase I and phase III trials. We're really enthusiastic that our partners at Eisai are launching this clinical study together with the Alzheimer's Clinical Trials Consortium. My view is that beginning earlier is the optimal strategy for, as it happens, all of these neurological diseases. We're eager to see what results come from that. I'm not sure I caught your question, but I hope my answer covered it.

Michel Vounatsos

executive
#11

During the time we were concentrating on the aducanumab submission, we provided backing for the preclinical work involving BAN2401. Once we receive a readout and a response from the FDA regarding our path forward, we will return to discussing lifecycle management possibilities across the full disease continuum for patients.

Geoff Meacham

analyst
#12

Hi, everyone. Thanks for asking. Jeff, I'd also like to mention how much I've enjoyed collaborating with you. Here's another one about aducanumab. I realize an FDA ruling is what comes next. Looking at ENGAGE compared with EMERGE, I'm curious whether you could share any specifics about the review that your team has conducted alongside the FDA over, let's say, the last 6 to 9 months — could that be made public, or presented at a medical conference, or is there anything else you're able to tell us regarding how things have progressed over essentially the period starting at the beginning of this year? Thank you.

Joe Mara

executive
#13

Jeff, just so I'm clear on what you're really asking, your question is more about the schedule for the coming months?

Geoff Meacham

analyst
#14

No, I'm just talking about how solid the analysis is and the specifics of the data work on aducanumab that backs up the filing.

Alfred Sandrock

executive
#15

Honestly, Geoff, I'm not certain I caught what you asked, but my understanding is that three studies form the basis of the filing: EMERGE, ENGAGE, and PRIME. In EMERGE, you see the first study demonstrating an impact on the primary endpoint, and beyond that, on each of the three pre-specified secondary endpoints. When it comes to ENGAGE, which was a negative study, we feel that parts of its data do lend support to the analysis we carried out with EMERGE. Then there's PRIME, already published, where the clinical endpoints were exploratory ones, and on the highest dose an effect showed up on MMSE and on CDR-Sum of Boxes too. Once again, it was quite similar in that the lower doses didn't really produce much of an effect. That lines up with what ENGAGE and EMERGE found — you truly have to reach the higher dose. All of our data, I'd say, are consistent with that.

Geoff Meacham

analyst
#16

Okay, thanks, Al.

Umer Raffat

analyst
#17

Hi everyone, and thanks for the question. If I could zero in on Tecfidera and Vumerity for a moment. Michel, you brought up that two lifecycle management programs are underway, for Plegridy and Tysabri. To me, the lifecycle management program that matters most is Vumerity, which has been available for several months yet has lagged badly. So my question is: what explains that, and why does nearly every prior case of lifecycle management grab a share well beyond 25%, reaching as high as 80%? I'd really like to hear how you see this from a commercial standpoint.

Michel Vounatsos

executive
#18

Yeah, thanks for asking. I too am disappointed by how VUMERITY has performed so far. Given the patent life we hold, we can expect that we're pursuing lifecycle management opportunities over the long term; we brought VUMERITY to market in December, and the start forms looked encouraging. Then COVID arrived, and it hit patients, new starts, and switchers hard. When we launched in December, we didn't expect that COVID would be here three months later. Back then, as you'll recall, since you raised the question several times, the approach wasn't a switch strategy — it was a fumarate strategy aimed at growing the fumarate share. The results aren't bad. That isn't a justification for Vumerity's shortfall so far, and the U.S. organization is fully engaged on it. What it demonstrates is that launching during a shutdown is hard and challenging. Altering behavior is challenging when you can't see the prescriber. That said, the whole focus has now shifted to Vumerity. The timing is favorable since our access is very good, near 90%. We've boosted resource allocation substantially; this is a next-generation fumarate backed by solid data. Vumerity stands apart, as you're aware, when it comes to GI tolerability; that doesn't mean every patient on Tecfidera would gain from Vumerity, since those who are stable ought to remain on Tecfidera. The organization now has a much stronger focus on a single brand — Vumerity, the new-generation fumarate — and the coming months ought to tell the story. We're not giving up, and neither should you.

Marc Goodman

analyst
#19

Yes, hello. Jeff, I wanted to ask about the SG&A outlook. It seems to be $300 million lower than previously. Your planned spending increase for Adu in the latter half of the year hasn't changed at all. So where exactly are these reductions coming from?

Jeffrey Capello

executive
#20

Thank you, Marc. During this pandemic, we've obviously seen far less travel happening, far fewer conferences, meetings, and other optional expenses. The bulk of that guidance difference stems from the significant savings we achieved in the second quarter, and we expect those savings to persist through the back half of the year.

Jay Olson

analyst
#21

Oh, hey there. Thanks for taking my question. Given that the aducanumab BLA was submitted in a modular fashion, could you say something about whether the FDA started a rolling review of those modules, or did they hold off until the whole BLA submission was in before they began reviewing it? Thank you.

Alfred Sandrock

executive
#22

Well, commenting on what goes on inside the FDA isn't something I want to do. It is accurate that we filed modules once they were ready to be filed; some of those modules have been in their hands for a number of months at this point. Whether they looked at them or not, that falls under FDA internal processes, and I'm not able to comment on it.

Jay Olson

analyst
#23

Thanks.

Michael Yee

analyst
#24

Morning, and congratulations on the progress — especially you, Al, on the filing. That was, as I understand it, unprecedented. Al, perhaps you could address one straightforward matter: how are you thinking about priority review, is there any chance it wouldn't be granted, and did you rationally make use of a voucher? You said something encouraging regarding Europe and your preparations to file there. Have you actually spoken with them and reached a comparable kind of agreement? Please just give your thoughts on Europe. Many thanks.

Michael Yee

analyst
#25

I'm not muted.

Terence Flynn

analyst
#26

Great, thanks for taking the question. Mine may have two parts. Jeff, I was wondering whether you could say what prompted the revision to the revenue guidance, with any additional specifics, and does your assumption include SPINRAZA growing during the back half of the year? More broadly, perhaps a question for Al: can you confirm IQVIA served as the CRO for the adu phase III trials, and I'm curious how involved the company was in the filing process and whether they took part in the discussions with the FDA. Thank you.

Alfred Sandrock

executive
#27

Hi, this is Al Sandrock. Michael may not have caught my earlier answer, so I'll say it again. Regarding priority review, we do hold a voucher. One came to us when nusinersen was approved, but we haven't said anything about how or when we'll use it. We do expect to learn whether priority review has been granted when the FDA informs us that the filing has been accepted. That's all I'll say on it. As for the ex-U.S. regulators, which I believe was the second part of your question: we have engaged formally with the EMA, and a filing for the European submission is being prepared; we've also had informal interactions with the Japanese regulators, and that filing is being prepared as well.

Jeffrey Capello

executive
#28

Perhaps turning to Terence's question regarding what caused the guidance discrepancy. I would direct you back to Q1, when we kept guidance unchanged despite the COVID pandemic, since we preferred to observe how events unfolded. Now, here at the close of July, we understand more clearly the second quarter's effect. It involved both the reversal of Q1 activity that we outlined, along with certain pressures in a few businesses such as SPINRAZA and TYSABRI. We anticipate a portion of those pressures will persist through the latter half of the year. Most of the guidance gap stems from ongoing COVID consequences, something hard to foresee at the time we issued guidance. I would add that we witnessed meaningful business strengthening across the second quarter's months, especially in the U.S. SMA business, where April proved quite difficult, followed by improvement in May and then considerable improvement in June. One more remark: we chose a relatively wide range since we are still gauging how fast recovery arrives. The main factor is the full-year COVID effect pushing guidance lower; we did observe encouraging strengthening in SPINRAZA. Time will tell how everything unfolds.

Alfred Sandrock

executive
#29

There's something I wanted to address regarding IQVIA. That's right — IQVIA served as the CRO assisting us with the phase III studies for aducanumab. That said, when it came to the regulatory discussions we've conducted with FDA, they played no part in those.

Matthew Harrison

analyst
#30

Thank you. Good morning, and I appreciate the question. First off, Al, could you clear up your earlier remark regarding the priority review voucher? It seems you're avoiding a statement about whether it was used when filing for Adu. Second, would you share your thoughts on anti-LINGO-1? What outcome would you consider a positive one from that trial? And what has to be shown before it advances to phase III? Thanks.

Alfred Sandrock

executive
#31

Hello, Matthew. Yes, with respect to the prior, that's correct. Whether our priority voucher has been used is something we won't discuss. As for anti-LINGO-1, the primary endpoint we're looking at goes by the name Overall Response Score. This composite consists of four parts: it assesses walking, EDSS, the Nine-Hole Peg Test for the dominant hand, and the Nine-Hole Peg Test for the non-dominant hand. That's four separate components. What we're trying to determine is if there's general improvement across the board, since, as everyone knows, multiple sclerosis impacts various regions of the central nervous system. Sometimes a patient gets better in one aspect while getting worse in another. Our goal was to find out if, on the whole, patients are improving. Beyond that, naturally, we'll also be examining imaging-based indicators tied to myelination. Take magnetization transfer ratio, or MTR — it does a solid job of capturing how much myelin you have, so that's one we intend to examine. Beyond the clinical side, we also want to check whether any biological measurements we gather line up with what we'd expect from myelination.

Ronny Gal

analyst
#32

Morning, everyone. Nice results — congrats, and thanks for fielding the question. Earlier, ahead of the submission, you laid out several aducanumab datasets, different patient cuts, and you told us you'd done the same, and actually more than that, with the FDA. Could you tell us which primary patient cut serves as the basis for the review? Is it the full certification — everyone who got some number of high doses versus placebo? If you can take a shot at that, I'd also like to know whether you're leaning on copay and rebate differences to push VUMERITY adoption going forward, or whether it's simply a shift in where the organization puts its educational emphasis?

Alfred Sandrock

executive
#33

Ronny, I'll handle the first part. From the three studies I named — EMERGE, ENGAGE, and PRIME — we submitted all the data. Whatever the FDA opts to examine falls under their purview. Regarding the negative trial, ENGAGE, I'd note we have analyses demonstrating that patients who got the top dose across a sustained period do show efficacy evidence comparable to what we saw in EMERGE. Those are the data we shared at CTAD and at ADPD, and that's the basis for our belief that supportive evidence emerges from ENGAGE.

Michel Vounatsos

executive
#34

As for the second half of what you asked, Ronny, regarding VUMERITY — because the spotlight these days is on VUMERITY rather than the fumarates — what I can say is that alignment exists across every level. At the payer level, at patient services, at the sales force, which includes incentive programs designed to drive behavior, and at medical affairs. The whole organization is fully aligned and concentrated on each of those levels. The coming 5 months are going to be decisive.

Ronny Gal

analyst
#35

Thank you.

Phil Nadeau

analyst
#36

Good morning, and thanks for taking my question. Jeff, I'd also like to wish you well as you head off to your next opportunity. I appreciate your assistance through the years. Al, this one's for you. During the prepared remarks, you indicated that the FDA and the pre-BLA meeting observed that filing aducanumab on the basis of the three studies is reasonable. I'm wondering if you could share any additional information about that pre-BLA meeting. Which topics came up? What kind of feedback came your way? Perhaps specifically, did the FDA give any signal about whether an advisory committee would probably happen? Thanks.

Alfred Sandrock

executive
#37

Hi, Phil. Yes. Our policy is that we don't discuss what happens in our regulatory interactions, so going beyond what I stated in my prepared remarks isn't something I'm ready to do. Regarding the advisory committee, it wouldn't be out of the ordinary for the first disease-modifying therapy of this kind to go before an advisory committee. We're beginning preparations for one. Whether one takes place, and the timing of it, will be determined by the FDA, and we anticipate learning that around when we're told whether the file has been accepted.

Phil Nadeau

analyst
#38

Great. Thank you.

Tim Anderson

analyst
#39

Thank you. I'd like to ask about aducanumab. Regarding tau as a biomarker—its importance in Alzheimer's has grown considerably in recent years, whether it's measured through PET, serum, or CSF. Relative to the scale of ENGAGE and EMERGE, the tau biomarker data you gathered was fairly limited. I'm curious what feedback the FDA has given you about this, specifically whether they want additional tau biomarker data. From what I understand, in the new EMBARK study, you're collecting tau from every participant. I believe that involves tau imaging as well. Any thoughts on this would be appreciated. You've been open about seeking a priority review, but what I haven't heard you mention is whether you've also applied for breakthrough therapy designation, which is arguably a stronger indicator of how the FDA regards your data. Thank you.

Alfred Sandrock

executive
#40

Tim, you're correct that tau has become more prominent as a key biomarker and possibly a drug target in Alzheimer's disease; the reason is that tau accumulation appears to correlate most strongly with clinical progression. That said, we believe amyloid beta and tau interact with each other, and it's conceivable that tau could be triggered—tau misfolding and spreading could be set off by various factors, trauma being one, but amyloid beta might do so as well. Our data would support that, since when we reduced—we used aducanumab, which targets amyloid beta specifically, and we observe downstream effects on tau, both through imaging and through CSF. The reason the patient count isn't very high is that, first, it's difficult to persuade patients to have a lumbar puncture done twice. Also, we were bringing in a new tau PET imaging ligand, and we were already doing amyloid imaging on patients. Requiring two PET scans, two separate kinds of PET scans, is a great deal to ask of patients; we do believe we have sufficient data to demonstrate a convincing effect on tau, not just in the CSF, but through imaging too. I've now lost track of the second part of your question.

Tim Anderson

analyst
#41

About the breakthrough designation.

Alfred Sandrock

executive
#42

Ah, the breakthrough. Right. So Fast Track status is something we already hold, and we anticipate getting word regarding a priority review; having that Fast Track designation lets us interact with FDA, and I want to say how grateful we are for how involved they've been, really from June of last year onward, during which we've enjoyed many productive and cooperative exchanges with FDA.

Tim Anderson

analyst
#43

Thanks.

Brian Abrahams

analyst
#44

Hello. I appreciate you fitting in my question. I'd like to ask about SPINRAZA and what's happening with SMA. Regarding the fresh trial involving gene therapy as a combination, what results are you expecting? From a reimbursement standpoint, is there a particular threshold people might anticipate for using them together? Could you also speak to any further commercial readiness or changes in approach before an oral option possibly arrives? Thanks.

Alfred Sandrock

executive
#45

Brian, I'll handle the first portion. The primary driver for running this trial is that, first, physicians have already been prescribing it this way, yet no study data exists showing whether patients benefit. As a matter of fact, the European Journal of Paediatric Neurology recently released a consensus statement from European SMA specialists. They highlight a genuine shortage of evidence regarding this combo treatment; they urged additional research into it. We're glad to be conducting one. The central issue is: when you combine SPINRAZA with ZOLGENSMA, or ZOLGENSMA with SPINRAZA, do you observe gains past what either single therapy delivers by itself? Essentially, we're examining motor milestones—if they're sustained more effectively, if additional motor milestones are achieved. It's primarily a matter of efficacy.

Michel Vounatsos

executive
#46

I believe it's really beneficial to assist clinicians in ranking which therapeutic option to choose according to research rather than speculation or claims. Regarding the competitive landscape for risdiplam, speculation remains difficult since no label exists as of yet. FIREFISH came out pretty consistent. In terms of hitting the objectives, SUNFISH was underwhelming. When I talk with scientific leaders, their stance is that we must wait for the long-term safety and efficacy profile of the product. As for the gene therapy, I think we have a profile that is starting to become well-characterized. If I go back to the latest consensus published in the "European Journal of Paediatric Neurology," uncertainty remains regarding the older population's behavior, the infant, ease, and they perceive a connection to the potential risk regarding weight. Essentially, the scientific leaders encourage examining other options. At Biogen, we stand behind Spinraza's efficacy and safety across all age groups, and our body of evidence is larger. The product now has approval in 50 countries. We believe Spinraza will keep being truly a very good treatment and alternative in this context, where there is a bit more treatment in this market, which is good for the patients; we are working to enhance the efficacy by increasing the dose. I'm not sure others can do that. Last but not least, there is the RESPOND study after gene therapy. I think it's good in order to best educate the market. We are confident.

Joe Mara

executive
#47

thank you, Michel, and thank you, Al.

Alfred Sandrock

executive
#48

we can take roughly two additional questions.

Evan Seigerman

analyst
#49

Hello, everyone. I really appreciate you taking my question, and congratulations on the progress. In last night's press release about Mike's appointment, you clearly highlighted his knowledge in — and I'm quoting here — "value-creating strategic financial considerations." Should we interpret that as a shift toward more or bigger transformative business development? Since under Jeff's leadership, there was really just a single major deal, and that was the Nightstar acquisition.

Michel Vounatsos

executive
#50

Well, alongside Jeff, we got 18 deals done. Keep in mind, we think we hold equity in the area where we specialize. The sweet spot is early stage; that's where we're able to contribute the most value. It makes me very happy to watch this portfolio mature remarkably well, with highly significant readouts over the next 12 months and past that, which will begin affecting the market in 2024, 2025. Between right now and that 2024 to 5 period, one major hope exists, and that is aducanumab. I can share that we remain quite active when it comes to the BD M&A front. At the same time, we're being very cautious as we potentially approach aducanumab. We will always put money to work for the sake of long-term shareholder value creation.

Evan Seigerman

analyst
#51

All right. Appreciate it.

Robyn Karnauskas

analyst
#52

All right. I appreciate you fielding this. Thanks for the transition, Evan. I'd like to ask about the phase III STAR trial in choroideremia. There's data on the way. Yours will be the first. Could you lay out what the hurdle looks like, and what the optimal outcome would be for getting the strongest reimbursement for this drug? And what would follow in order to treat patients who are even younger, since a lot of people develop this disease at a very early age? Thanks.

Alfred Sandrock

executive
#53

Hello, Robyn. Al here. Yes, so BIIB111 is our gene therapy aimed at choroideremia. Roughly 160 patients are in the phase III study. As you mention, the bar, or the primary endpoint, is the percentage of patients showing an improvement of more than 15 letters versus baseline in best-corrected visual acuity. That is what the FDA requires. It's a two-arm study with placebo, so all we need is for treated patients to show greater visual acuity improvement than those who are not treated. Enrollment in this trial began in December of 2017. Our last patient was announced in November of 2019, so a readout should come in the first quarter of next year. This phase III study follows a phase I study, which was single-arm, and it looked at the proportion of patients with a best-corrected visual acuity gain compared with a natural history study. On that endpoint, the drug showed some quite encouraging results. For phase III, we're essentially employing that same endpoint and attempting to meet the FDA's standard.

Joe Mara

executive
#54

Appreciate it. Michel, I'd like to turn things over to you now for a few final remarks, if you would.

Michel Vounatsos

executive
#55

Much appreciated, Joe. I'm grateful that everyone could join us. Once more, I'd like to express my thanks to Jeff for everything he has done for this organization. Here at Biogen, neuroscience pioneering is what defines us; we're entering a truly thrilling period spanning more than 40 years of our work in development. The pipeline we've built, along with the extensive capital we've directed toward that area, is now coming to fruition. Over the next 10 months, several highly significant readouts await us; 7 of them are Phase III, and assuming the FDA gives the green light, we stand on the verge of turning a brand-new page with aducanumab. I appreciate everyone's time and focus.

Read the full transcript via the API

You're viewing the first half of this call. Get the complete Biogen Inc. transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.

Get the API View API docs →

This call discussed

For developers and AI pipelines

Programmatic access to Biogen Inc. earnings transcripts and 132,000+ others is available through the EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments, full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.

More tools for stock research

OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Biogen Inc. or any ticker on your watchlist.

StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.